This study is looking at the safety and effects of an updated COVID-19 vaccine called BNT162b2 in healthy adults aged 18 to 64. You might be able to join if you are medically stable, haven't had COVID-19 recently, and haven't received another vaccine recently. Participants will receive one injection of either the BNT162b2 vaccine or a Tdap vaccine (for tetanus, diphtheria, and whooping cough). Neither you nor the study team will know which vaccine you receive. Researchers will check for any reactions or side effects to understand how safe the vaccines are. The study aims to enroll 200 people, but its current recruitment status is unclear.

Study design

This is an interventional study where participants will randomly receive one of two vaccines. The study plans to enroll 200 participants.

What's involved

Participants will receive a single injection on Day 1. Researchers will monitor for local reactions and systemic events for 7 days, and for adverse events for 1 month.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for serious adverse events for up to 12 months after vaccination.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.